PTEN and melanoma: Furthermore, VO-OHpic treatment of mice with established melanoma or lymphoma tumors resulted in the induction of an inflammatory antitumor response [132], suggesting that pharmacological inhibitory targeting of PTEN could add benefits to anticancer immunotherapies.